S&P 500   3,374.96 (+0.05%)
DOW   27,912.06 (+0.05%)
QQQ   272.65 (+0.06%)
AAPL   459.23 (-0.18%)
MSFT   209.16 (+0.22%)
FB   260.60 (-0.27%)
GOOGL   1,514.58 (-0.14%)
AMZN   3,152.68 (-0.26%)
NVDA   462.29 (+1.00%)
CGC   17.27 (-0.29%)
BABA   252.28 (-0.57%)
TSLA   1,645.75 (+1.53%)
GE   6.64 (+0.61%)
MU   45.98 (-0.35%)
AMD   81.49 (-0.43%)
T   30.04 (+0.43%)
F   7.08 (+0.71%)
ACB   10.69 (+5.01%)
GILD   68.73 (+0.81%)
NFLX   483.81 (+0.52%)
DIS   130.47 (-0.37%)
BAC   26.52 (+0.65%)
BA   177.31 (+1.48%)
S&P 500   3,374.96 (+0.05%)
DOW   27,912.06 (+0.05%)
QQQ   272.65 (+0.06%)
AAPL   459.23 (-0.18%)
MSFT   209.16 (+0.22%)
FB   260.60 (-0.27%)
GOOGL   1,514.58 (-0.14%)
AMZN   3,152.68 (-0.26%)
NVDA   462.29 (+1.00%)
CGC   17.27 (-0.29%)
BABA   252.28 (-0.57%)
TSLA   1,645.75 (+1.53%)
GE   6.64 (+0.61%)
MU   45.98 (-0.35%)
AMD   81.49 (-0.43%)
T   30.04 (+0.43%)
F   7.08 (+0.71%)
ACB   10.69 (+5.01%)
GILD   68.73 (+0.81%)
NFLX   483.81 (+0.52%)
DIS   130.47 (-0.37%)
BAC   26.52 (+0.65%)
BA   177.31 (+1.48%)
S&P 500   3,374.96 (+0.05%)
DOW   27,912.06 (+0.05%)
QQQ   272.65 (+0.06%)
AAPL   459.23 (-0.18%)
MSFT   209.16 (+0.22%)
FB   260.60 (-0.27%)
GOOGL   1,514.58 (-0.14%)
AMZN   3,152.68 (-0.26%)
NVDA   462.29 (+1.00%)
CGC   17.27 (-0.29%)
BABA   252.28 (-0.57%)
TSLA   1,645.75 (+1.53%)
GE   6.64 (+0.61%)
MU   45.98 (-0.35%)
AMD   81.49 (-0.43%)
T   30.04 (+0.43%)
F   7.08 (+0.71%)
ACB   10.69 (+5.01%)
GILD   68.73 (+0.81%)
NFLX   483.81 (+0.52%)
DIS   130.47 (-0.37%)
BAC   26.52 (+0.65%)
BA   177.31 (+1.48%)
S&P 500   3,374.96 (+0.05%)
DOW   27,912.06 (+0.05%)
QQQ   272.65 (+0.06%)
AAPL   459.23 (-0.18%)
MSFT   209.16 (+0.22%)
FB   260.60 (-0.27%)
GOOGL   1,514.58 (-0.14%)
AMZN   3,152.68 (-0.26%)
NVDA   462.29 (+1.00%)
CGC   17.27 (-0.29%)
BABA   252.28 (-0.57%)
TSLA   1,645.75 (+1.53%)
GE   6.64 (+0.61%)
MU   45.98 (-0.35%)
AMD   81.49 (-0.43%)
T   30.04 (+0.43%)
F   7.08 (+0.71%)
ACB   10.69 (+5.01%)
GILD   68.73 (+0.81%)
NFLX   483.81 (+0.52%)
DIS   130.47 (-0.37%)
BAC   26.52 (+0.65%)
BA   177.31 (+1.48%)
Log in

NASDAQ:TTPHTetraphase Pharmaceuticals Stock Price, Forecast & News

$2.20
-0.08 (-3.51 %)
(As of 08/14/2020 12:48 PM ET)
Add
Compare
Today's Range
$2.18
Now: $2.20
$2.27
50-Day Range
$2.20
MA: $2.39
$2.77
52-Week Range
$0.56
Now: $2.20
$8.60
Volume282,600 shs
Average Volume932,542 shs
Market Capitalization$15.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Read More
Tetraphase Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.38 million
Book Value$6.68 per share

Profitability

Net Income$-70,080,000.00
Net Margins-798.18%

Miscellaneous

Employees119
Market Cap$15.98 million
Next Earnings DateN/A
OptionableOptionable
$2.20
-0.08 (-3.51 %)
(As of 08/14/2020 12:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

How has Tetraphase Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Tetraphase Pharmaceuticals' stock was trading at $1.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TTPH stock has increased by 40.1% and is now trading at $2.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tetraphase Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tetraphase Pharmaceuticals
.

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) EPS for the quarter, beating the Zacks' consensus estimate of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.45 million. Tetraphase Pharmaceuticals had a negative net margin of 798.18% and a negative return on equity of 210.86%.
View Tetraphase Pharmaceuticals' earnings history
.

When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work?

Tetraphase Pharmaceuticals shares reverse split before market open on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2019. An investor that had 100 shares of Tetraphase Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

Has Tetraphase Pharmaceuticals been receiving favorable news coverage?

News headlines about TTPH stock have trended somewhat negative on Friday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Tetraphase Pharmaceuticals
.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 219,000 shares, a decrease of 40.6% from the June 15th total of 368,900 shares. Based on an average daily volume of 1,810,000 shares, the short-interest ratio is currently 0.1 days. Currently, 4.0% of the shares of the company are sold short.
View Tetraphase Pharmaceuticals' Short Interest
.

Who are some of Tetraphase Pharmaceuticals' key competitors?

What other stocks do shareholders of Tetraphase Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), Opko Health (OPK), Novavax (NVAX), Bank of America (BAC), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Inovio Pharmaceuticals (INO) and Sorrento Therapeutics (SRNE).

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the following people:
  • Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)
  • Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)
  • Dr. Jacques Dumas, Chief Scientific Officer (Age 53)
  • Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)
  • Mr. Larry G. Edwards, Chief Operating Officer (Age 47)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

Who are Tetraphase Pharmaceuticals' major shareholders?

Tetraphase Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.32%). Company insiders that own Tetraphase Pharmaceuticals stock include Guy Macdonald, Jacques Dumas, John Gordon Freund and Jolla Pharmaceutical Co La.
View institutional ownership trends for Tetraphase Pharmaceuticals
.

Which major investors are selling Tetraphase Pharmaceuticals stock?

TTPH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have sold Tetraphase Pharmaceuticals company stock in the last year include Guy Macdonald, and John Gordon Freund.
View insider buying and selling activity for Tetraphase Pharmaceuticals
.

How do I buy shares of Tetraphase Pharmaceuticals?

Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of TTPH stock can currently be purchased for approximately $2.20.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $15.98 million and generates $7.38 million in revenue each year. The biopharmaceutical company earns $-70,080,000.00 in net income (profit) each year or ($22.85) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe.

What is Tetraphase Pharmaceuticals' official website?

The official website for Tetraphase Pharmaceuticals is www.tphase.com.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL WAY, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.